Basit öğe kaydını göster

Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR)

dc.contributor.authorALHAN, ASLIHAN
dc.contributor.authorOlgun, Fatih Erkam
dc.contributor.authorDemirkan, Burcu
dc.contributor.authorAtas, Ali Ekber
dc.contributor.authorKilicaslan, Fethi
dc.contributor.authorAltay, Hakan
dc.contributor.authorTengiz, Istemihan
dc.contributor.authorErkan, Aycan Fahri
dc.contributor.authorKilicaslan, Baris
dc.contributor.authorEKİCİ, BERKAY
dc.contributor.authorYaman, Mehmet
dc.contributor.authorKÜÇÜK, MURATHAN
dc.contributor.authorZOGHİ, MEHDİ
dc.contributor.authorDURAKOĞLUGİL, MURTAZA EMRE
dc.contributor.authorDereli, Seckin
dc.contributor.authorYenercag, Mustafa
dc.contributor.authorYigit, Zerrin
dc.contributor.authorBas, Mehmet Memduh
dc.contributor.authorKARAVELİOĞLU, YUSUF
dc.contributor.authorCakmak, Huseyin Altug
dc.contributor.authorKivrak, Tarik
dc.contributor.authorOzkan, Hakan
dc.contributor.authorAltin, Cihan
dc.contributor.authorSabanoglu, Cengiz
dc.date.accessioned2021-12-10T10:27:59Z
dc.date.available2021-12-10T10:27:59Z
dc.date.issued2021
dc.identifier.citationEKİCİ B., Yaman M., KÜÇÜK M., Dereli S., Yenercag M., Yigit Z., Bas M. M. , KARAVELİOĞLU Y., Cakmak H. A. , Kivrak T., et al., "Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR)", TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, cilt.49, sa.5, ss.357-368, 2021
dc.identifier.othervv_1032021
dc.identifier.otherav_4102effc-ab0b-4e96-ab77-9126c7aed08a
dc.identifier.urihttp://hdl.handle.net/20.500.12627/169930
dc.identifier.urihttps://doi.org/10.5543/tkda.2021.63099
dc.description.abstractObjective: Heart failure (HF) is a growing public health problem with high morbidity and mortality. Recently, angiotensin receptor neprilysin inhibitor (ARNi) has emerged as a promising treatment for HF with reduced ejection fraction (HFrEF). Here, we shared our experience with the use of ARNi in HFrEF from multiple centers in Turkey.
dc.language.isoeng
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectKardiyoloji
dc.subjectCardiology and Cardiovascular Medicine
dc.subjectHealth Sciences
dc.subjectCARDIAC ve CARDIOVASCULAR SİSTEMLER
dc.titleAngiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR)
dc.typeMakale
dc.relation.journalTURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY
dc.contributor.departmentUfuk Üniversitesi , ,
dc.identifier.volume49
dc.identifier.issue5
dc.identifier.startpage357
dc.identifier.endpage368
dc.contributor.firstauthorID2694710


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster